Why is Mereo BioPharma being investigated by securities attorneys?

Mereo BioPharma is under investigation over allegations it misled investors about the true performance of its Phase 3 ORBIT and COSMIC clinical trials, which reportedly failed to meet their primary efficacy endpoints.

What are the ORBIT and COSMIC trials at Mereo BioPharma?

ORBIT and COSMIC are Phase 3 clinical programs evaluating Mereo drug candidates for fracture risk reduction, and their outcomes were critical to regulatory approval and the company’s future valuation.

What does it mean that a clinical trial missed its primary endpoint?

Missing a primary endpoint means the drug did not show statistically significant benefit versus a control, which can derail approval prospects and materially impact a biotech company’s stock price.

What are investors alleging about Mereo BioPharma’s disclosures?

Investors allege Mereo overstated or failed to fully disclose trial risks and outcomes, creating a misleading impression of drug efficacy that later harmed shareholders when results became clear.

What is the deadline to seek lead plaintiff status in the Mereo BioPharma lawsuit?

Investors seeking to serve as lead plaintiff in the federal securities class action against Mereo BioPharma must file a motion by April 6, 2026, to preserve their right to represent the class.

Mereo BioPharma Group plc - Faruqi & Faruqi LLP

Mereo BioPharma Group plc

Join Action

Case Details

Ticker MREO

Class Period 06/05/2023 - 12/26/2025

Lead Plaintiff Deadline 04/06/2026

Days Left to Seek Plaintiff

If you are a Mereo BioPharma investor who suffered a loss and would like to learn more, you can provide your information below:

If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit its primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups, respectively.

Lead Plaintiff Deadline: April 6, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Mereo BioPharma Group plc

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify